- Novartis, Vertex and Ipsen extend pharma M&A spree from 2026's first halfBiopharma's M&A engine is revved up and shows no signs of cooling off. Four companies have announced acquisitions in the first six days of July, forging deals that could pay out as much as $1…Endpoints · 19d ago↗ source
- MeiraGTx strikes royalty deal; Fore's 2023 Series D continuesPlus, news about Kalohexis, Teva and Agios: 👑 MeiraGTx makes royalty deal with Oberland Capital: The gene therapy maker will get an initial $135 million via a $10 million equity investment ...Endpoints · 19d ago↗ source
- STAT+: ‘Secret shopper’ study probes GLP-1 telehealth sitesIn this edition of STAT Health Tech: A 'secret shopper' study of telehealth sites prescribing GLP-1s, news about Epic, Anthropic, and brain implants.